Harvard Bioscience ( (HBIO) ) has released its Q3 earnings. Here is a breakdown of the information Harvard Bioscience presented to its investors.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Harvard Bioscience, Inc. is a prominent developer and manufacturer in the life sciences sector, providing technologies and services for research, drug discovery, and preclinical testing, with a global presence in the United States, Europe, and China.
In its third-quarter 2025 financial results, Harvard Bioscience reported revenues of $20.6 million, a slight decrease from the previous year, but highlighted an improved gross margin and positive cash flow from operations. The company also noted a significant reduction in net loss compared to the same period last year.
Key financial metrics showed a gross margin of 58.4% and an adjusted EBITDA of $2.0 million, reflecting operational improvements. The company is actively working on refinancing or repaying its debt in the upcoming quarter, which is expected to strengthen its financial position. Additionally, the company has seen increased customer engagement and order growth, contributing to a robust backlog.
Looking ahead to the fourth quarter, Harvard Bioscience anticipates revenues between $22.5 million and $24.5 million, with gross margins ranging from 58% to 60%. The company remains focused on maintaining strong financial discipline and capitalizing on increased demand to drive further growth.